UNSPSC 51452402: Diethylcarbamazine

This classification denotes an antihelminthic agent with the molecular formula C10H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V867Q8X3ZD, chemically known as 4-methyl-n,n-bis(4-methylpiperazin-2-yl)-piperazine-1-carboxamide but generally known as diethylcarbamazine, which bears US NIH Compound Identifier 3052. European Medicines Agency schedules Diethylcarbamazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07111MIG. The term DIETHYLCARBAMAZINE is an International Non-Proprietary Name.

UNSPSC 51452402 Diethylcarbamazine, a Commodity code, shows little relevant recent activity in state and local procurement. The code nominally covers a specific antiparasitic pharmaceutical ingredient, but the recent opportunities tagged under it involve naloxone (an opioid antagonist), general medical and first aid supplies for emergency responders, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products—none of which align with diethylcarbamazine procurement. The mismatch between the code's narrow scope and the breadth of pharmaceutical and medical-supply work appearing under it suggests either miscoding in source systems or a systemic issue with how these jurisdictions classify pharmaceutical purchases.

The issuing bodies in the recent records span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire and rescue operations (City of Tampa), and cooperative purchasing alliances serving multi-state participation (Minnesota Multistate Cooperative Purchasing Alliance). The geographic spread includes Florida, Texas, and Minnesota. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's invitation to bid for medical and first aid supplies with an estimated contract value of $700,000 and SLBE set-aside designation (due March 13, 2026), Texas HHS's Request for Information on direct-to-manufacturer prescription programs (due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). If your firm pursues pharmaceutical or medical-supply contracts with state and local buyers, verify the correct UNSPSC classification in each jurisdiction's procurement system before responding, as the diethylcarbamazine code does not reliably describe current buying activity.